Sage Therapeutics Inc Share Price (NASDAQ: SAGE)

$8.7

Last updated on July 30, 2025 at 12:00 AM IST

$₹

The stock has been delisted from the stock exchange on 30 Jul 2025

Check the interactive Sage Therapeutics Inc Stock chart to analyse performance

Sage Therapeutics Inc Key Stats

Check Sage Therapeutics Inc key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$8.7
Open	$8.735
Market Capitalization	$544.8M
Today's Volume	$22.7M
Revenue TTM	$47.4M
EBITDA	$-359.0M
Earnings Per Share (EPS)	$-5.8
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-63.53%

Global Institutional Holdings in Sage Therapeutics Inc

Name
Holdings %
Name
Holdings %
Vanguard Group Inc
8.11%
BlackRock Inc
7.44%
Madison Avenue Partners, LP
7.15%
Caligan Partners LP
4.87%
Test Hedge Fund Mgmt
4.36%
D. E. Shaw & Co LP
3.33%

Analyst Recommendation on Sage Therapeutics Inc Stock

Rating

Trend

Hold

33%Buy

62%Hold

3%Sell

Based on 27 Wall street analysts offering stock ratings for Sage Therapeutics Inc(by analysts ranked 0 to 5 stars)

Sage Therapeutics Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$6.9M	↓ 92.39%
Net Income	$-650.2M	↑ 74.36%
Net Profit Margin	-9.5K%	↓ 9053.32%

	FY20	Y/Y Change
Revenue	$1.1B	↑ 16123.06%
Net Income	$606.1M	↓ 193.22%
Net Profit Margin	54.4%	↑ 9520.78%

	FY21	Y/Y Change
Revenue	$6.3M	↓ 99.43%
Net Income	$-450.8M	↓ 174.38%
Net Profit Margin	-7.1K%	↓ 7201.31%

	FY22	Y/Y Change
Revenue	$7.7M	↑ 21.85%
Net Income	$-503.3M	↑ 11.63%
Net Profit Margin	-6.5K%	↑ 599.07%

	FY23	Y/Y Change
Revenue	$86.5M	↑ 1024.84%
Net Income	$-541.5M	↑ 7.59%
Net Profit Margin	-626.32%	↑ 5921.52%

	FY24	Y/Y Change
Revenue	$41.2M	↓ 52.3%
Net Income	$-400.7M	↓ 26.01%
Net Profit Margin	-971.48%	↓ 345.16%

Q4 FY23

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

	Q4 FY23	Q/Q Change
Revenue	$78.0M	↑ 2770.84%
Net Income	$-32.7M	↓ 83.78%
Net Profit Margin	-41.95%	↑ 7381.83%

	Q1 FY24	Q/Q Change
Revenue	$7.9M	↓ 89.87%
Net Income	$-108.5M	↑ 231.69%
Net Profit Margin	-1.4K%	↓ 1330.9%

	Q2 FY24	Q/Q Change
Revenue	$8.7M	↑ 9.52%
Net Income	$-102.9M	↓ 5.19%
Net Profit Margin	-1.2K%	↑ 184.34%

	Q3 FY24	Q/Q Change
Revenue	$11.9M	↑ 37.17%
Net Income	$-93.6M	↓ 9.04%
Net Profit Margin	-788.06%	↑ 400.45%

	Q4 FY24	Q/Q Change
Revenue	$12.8M	↑ 7.96%
Net Income	$-95.8M	↑ 2.38%
Net Profit Margin	-747.33%	↑ 40.73%

	Q1 FY25	Q/Q Change
Revenue	$14.1M	↑ 9.73%
Net Income	$-62.2M	↓ 35.04%
Net Profit Margin	-442.39%	↑ 304.94%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$6.5M	↓ 92.84%

	FY20	Y/Y Change
Profit	$1.1B	↑ 17117.61%

	FY21	Y/Y Change
Profit	$5.8M	↓ 99.48%

	FY22	Y/Y Change
Profit	$6.9M	↑ 19.43%

	FY23	Y/Y Change
Profit	$84.3M	↑ 1126.48%

	FY24	Y/Y Change
Profit	$31.8M	↓ 62.28%

Q4 FY23

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

	Q4 FY23	Q/Q Change
Profit	$77.2M	↑ 4160.19%

	Q1 FY24	Q/Q Change
Profit	$6.6M	↓ 91.4%

	Q2 FY24	Q/Q Change
Profit	$7.2M	↑ 9.26%

	Q3 FY24	Q/Q Change
Profit	$6.6M	↓ 9.02%

	Q4 FY24	Q/Q Change
Profit	$11.3M	↑ 71.8%

	Q1 FY25	Q/Q Change
Profit	$13.4M	↑ 18.37%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-528.7M	↑ 102.83%
Investing Cash Flow	$-143.2M	↓ 72.06%
Financing Cash Flow	$607.6M	↓ 7.85%

	FY20	Y/Y Change
Operating Cash Flow	$664.3M	↓ 225.64%
Investing Cash Flow	$442.7M	↓ 409.23%
Financing Cash Flow	$426.8M	↓ 29.77%

	FY21	Y/Y Change
Operating Cash Flow	$-378.2M	↓ 156.93%
Investing Cash Flow	$-1.0B	↓ 326.45%
Financing Cash Flow	$13.3M	↓ 96.88%

	FY22	Y/Y Change
Operating Cash Flow	$-460.0M	↑ 21.64%
Investing Cash Flow	$325.4M	↓ 132.46%
Financing Cash Flow	$3.1M	↓ 76.98%

	FY23	Y/Y Change
Operating Cash Flow	$-540.6M	↑ 17.51%
Investing Cash Flow	$442.9M	↑ 36.1%
Financing Cash Flow	$6.0M	↑ 96.32%

	FY24	Y/Y Change
Operating Cash Flow	$-267.2M	↓ 50.57%
Investing Cash Flow	$266.7M	↓ 39.79%
Financing Cash Flow	$10.7M	↑ 76.92%

Q4 FY23

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

	Q4 FY23	Q/Q Change
Operating Cash Flow	$-119.5M	↓ 12.03%
Investing Cash Flow	$42.1M	↓ 73.78%
Financing Cash Flow	$-262.0K	↓ 109.46%

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-37.8M	↓ 68.35%
Investing Cash Flow	$139.4M	↑ 231.51%
Financing Cash Flow	$1.6M	↓ 694.27%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-80.4M	↑ 112.62%
Investing Cash Flow	$-386.0K	↓ 100.28%
Financing Cash Flow	$8.1M	↑ 418.37%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-82.4M	↑ 2.4%
Investing Cash Flow	$81.1M	↓ 21098.45%
Financing Cash Flow	$1.0M	↓ 87.15%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-66.6M	↓ 19.19%
Investing Cash Flow	$46.6M	↓ 42.54%
Financing Cash Flow	$-2.0K	↓ 100.19%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-81.7M	↑ 22.79%
Investing Cash Flow	$45.8M	↓ 1.7%
Financing Cash Flow	$148.0K	↓ 7500.0%

About Sage Therapeutics Inc

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. The company offers ZURZUVAE, a neuroactive steroid positive allosteric modulator of GABA receptors targeting synaptic and extrasynaptic GABA receptors for the treatment of postpartum depression in adults. Its product pipeline also includes SAGE-324, a novel GABA receptor positive allosteric modulator for chronic oral dosing, including seizures in developmental and epileptic encephalopathies; and SAGE-319, an extrasynaptic-preferring GABA receptor positive allosteric modulator PAM for treating behavioral symptoms associated with neurodevelopmental disorders. In addition, the company is developing various product candidates, including SAGE-817 and SAGE-039 for the treatment of acute and chronic brain health disorders, including work on allosteric modulation of the GABA and NMDA receptor systems in the brain, as well as NMDA receptor negative allosteric modulator focusing on the treatments for neurodevelopmental disorders. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Organization	Sage Therapeutics Inc
Employees	353
CEO	Mr. Barry E. Greene
Industry	Health Technology

Key Management of Sage Therapeutics Inc

Name	Title
Mr. Barry E. Greene	President, CEO & Director
Mr. Christopher Benecchi	COO & Treasurer
Mr. Gregory Shiferman	Senior VP, General Counsel & Secretary
Mr. Michael Quirk Ph.D.	Chief Scientific Officer & Interim Head of R&D
Ms. Ashley Kaplowitz	Director of Investor Relations
Ms. Pamela Herbster	Senior VP and Chief People & Experience Officer
Dr. Helen Colquhoun	Senior Vice President of Drug Safety & Pharmacovigilance
Dr. Aaron Koenig M.D.	Medical Director of Early Clinical Development
Helen Rubinstein	Investor Relations Officer

Important FAQs about investing in SAGE Stock from India :

What is Sage Therapeutics Inc share price today?

Sage Therapeutics Inc share price today is $8.70 as on July 30, 2025 at 12:00 AM IST at the close of the market. Sage Therapeutics Inc share today touched a day high of {{1_rba_end}} and a low of {{1_rba_st}}.

What is the 52 week high and 52 week low for Sage Therapeutics Inc share?

Sage Therapeutics Inc share touched a 52 week high of {{rba_end}} and a 52 week low of {{rba_st}}. Sage Therapeutics Inc stock price today i.e. July 30, 2025 at 12:00 AM IST is closed at $8.70, lower by 23.93% versus the 52 week high.

How to invest in Sage Therapeutics Inc Stock (SAGE) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Sage Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Sage Therapeutics Inc Shares that will get you 0.1724 shares as per Sage Therapeutics Inc share price of $8.70 per share as on July 30, 2025 at 12:00 AM IST.

What is the minimum amount required to buy Sage Therapeutics Inc Stock (SAGE) from India?

Indian investors can start investing in Sage Therapeutics Inc (SAGE) shares with as little as ₹87.521 or $1 (as of August 24, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹875.21 in Sage Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on August 24, 2025). Based on Sage Therapeutics Inc share’s latest price of $8.70 as on July 30, 2025 at 12:00 AM IST, you will get 1.1494 shares of Sage Therapeutics Inc. Learn more about fractional shares .

What are the returns that Sage Therapeutics Inc has given to Indian investors in the last 5 years?

Sage Therapeutics Inc stock has given 0.0% share price returns and 18.0% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?

Discover More

Pioneer Municipal High Incom
$8.95
+0.56%
Portman Ridge Finance Corp
$12.27
+1.4%
Proshares Ultra Top Qqq
$50.47
+5.04%
Flex Lng Ltd
$26.80
+0.75%
Cps Technologies Corp
$3.14
-2.18%
Scpharmaceuticals Inc
$4.85
+6.13%
Lever Sha 2x Long Aal D Etf
$15.38
+14.35%
Bold Eagle Acquisition Corp
$10.37
-0.19%
Tjx Companies, Inc., The
$136.47
-0.76%

Explore all